关于"Annona muricata"的抗癌性质的LCMS/MS植物化学分析,分子,病理和免疫组织化学研究
Rehab H Abdallah1, Muneera S M Al-Saleem2, Wael M Abdel-Mageed3,4
1Department of Pharmacognosy, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Molecules (Basel, Switzerland)
|August 12, 2023
概括
安诺娜·穆里卡塔 (Annona muricata) 果实提取物显示出对小鼠埃里希瘤 (Ehrlich ascites carcinoma,EAC) 的显著抗癌特性. 用这些提取物治疗改善了瘤生长和肝损伤,突出了治疗潜力.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 癌症生物学 癌症生物学
背景情况:
- 安诺纳·穆里卡塔 (Annona muricata) 是一种热带植物,它具有可食用的果实,具有已知的治疗性质.
- 埃里希瘤 (Ehrlich ascites carcinoma,EAC) 是研究癌症进展和治疗疗效的一个模型.
研究的目的:
- 为了识别Annona muricata果实提取物中的植物成分.
- 在小鼠模型中研究这些提取物对EAC的抗癌作用.
主要方法:
- 使用LCMS/MS分析识别乙醇和水果提取物中的化合物.
- 在雄性白色老鼠中诱导EAC,然后用A. muricata提取物进行治疗.
- 用基因表达,组织病理学和免疫组织化学来评估治疗效果.
主要成果:
- LCMS/MS确定了388种成分,包括乙原素,类,黄类和类,其中有四种新型化合物的特征.
- 诱导EAC导致了促亡和抗亡基因失调,瘤生长和肝损伤.
- A. muricata 提取物显著改善了这些异常,减少了瘤负担和肝脏病理.
结论:
- 安诺纳·穆里卡塔 (Annona muricata) 果实提取物对EAC具有显著的抗癌活性.
- 这些提取物通过调节亡并减少与瘤相关的组织损伤,显示出在癌症治疗中具有治疗用途的潜力.
关键词:
安诺娜·穆里卡塔 (Annona muricata) 是一个美丽的城市.这种植物是Annonaceae.这就是巴克斯巴克斯巴克斯巴克斯.Bcl-2 的使用方法.在UPLC-ESI-MS/MS中使用.更多相关视频
07:50Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis
Published on: December 8, 2023
587
06:12Using Multiple Light Scattering to Examine the Stability of Phyllanthus emblica L. Extracts Obtained with Different Extraction Methods
Published on: April 14, 2023
674
相关概念视频
02:59Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
01:25Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K